CUREVO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://curevovaccine.com
Clinical Trials
2
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Phase 2
Active, not recruiting
- Conditions
- ShinglesHerpes Zoster
- Interventions
- Biological: Amezosvatein Antigen High Dose Arm ABiological: Amezosvatein Antigen Low Dose Arm BBiological: Amezosvatein Adjuvant Dose Arm DBiological: Amezosvatein Adjuvant Dose Arm FBiological: Amezosvatein Adjuvant Dose Arm HBiological: Amezosvatein Adjuvant Dose Arm JBiological: Amezosvatein Adjuvant Dose Arm L
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Curevo Inc
- Target Recruit Count
- 1516
- Registration Number
- NCT05304351
- Locations
- 🇺🇸
Curevo Investigational Site, Salt Lake City, Utah, United States
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Herpes ZosterVaricella Zoster
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Curevo Inc
- Target Recruit Count
- 90
- Registration Number
- NCT03820414
- Locations
- 🇺🇸
The Center for Pharmaceutical Research, Kansas City, Missouri, United States
News
GC Biopharma Partners with Curevo Vaccine to Manufacture Next-Generation Shingles Vaccine with Improved Tolerability
GC Biopharma has secured contract manufacturing rights for amezosvatein (CRV-101), a recombinant shingles vaccine designed to reduce injection-site pain and systemic reactions compared to current market leader Shingrix.
Curevo's Amezosvatein Shows Promise in Phase 2 Trial with Improved Tolerability for Shingles Vaccine
Curevo Vaccine's amezosvatein demonstrated non-inferiority to Shingrix in a Phase 2 trial, meeting all primary endpoints for immunogenicity.